DayTwo

DayTwo is the first evidence-based, actionable, microbiome platform in the market. The company leverages their first-rate scientific experience, with clinical trials in Israel and the United States, to address the large and pressing need of diabetes management and to bring food-as-medicine to global markets for people with type 2 and prediabetes. Via gut microbiome DNA analysis, the company's algorithm, are able to give users food recommendations for balancing their blood sugar levels. DayTwo's microbiome platform is built upon the largest full-shotgun database of gut-microbiome profiles worldwide, by Professors Eran Segal, who holds a Ph.D. in Computer Science and Genetics from Stanford University, and Immunologist Eran Elinav, M.D., Ph.D. at The Weizmann Institute of Science in Israel.